Top Page
Sino Biopharmaceutical
(1177)
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Sino Biopharmaceutical Business Overview & Revenue Model
Sino Biopharmaceutical Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.57B | 28.87B | 26.20B | 26.03B | 26.86B | 23.65B |
| Gross Profit | 24.99B | 23.53B | 21.21B | 21.54B | 21.53B | 18.46B |
| EBITDA | 6.11B | 6.11B | 6.98B | 6.69B | 19.87B | 5.66B |
| Net Income | 3.87B | 3.50B | 2.33B | 2.54B | 14.61B | 2.77B |
Balance Sheet | ||||||
| Total Assets | 74.89B | 65.41B | 63.60B | 64.06B | 60.54B | 47.21B |
| Cash, Cash Equivalents and Short-Term Investments | 19.82B | 14.60B | 14.12B | 16.92B | 15.79B | 16.43B |
| Total Debt | 11.96B | 9.78B | 12.58B | 13.98B | 12.12B | 14.21B |
| Total Liabilities | 29.12B | 22.63B | 25.43B | 26.12B | 22.81B | 24.79B |
| Stockholders Equity | 33.37B | 31.96B | 30.47B | 29.75B | 30.29B | 16.75B |
Cash Flow | ||||||
| Free Cash Flow | 2.89B | 5.22B | 4.36B | 4.56B | 3.47B | 3.47B |
| Operating Cash Flow | 3.16B | 6.62B | 6.07B | 6.27B | 5.37B | 5.33B |
| Investing Cash Flow | -7.29B | -1.71B | -756.98M | -4.07B | -2.52B | -7.85B |
| Financing Cash Flow | 1.58B | -6.32B | -6.55B | -3.19B | -3.23B | 2.23B |
Sino Biopharmaceutical Technical Analysis
Sino Biopharmaceutical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | HK$68.78B | 26.48 | 15.34% | 0.95% | 7.51% | 44.09% | |
63 Neutral | $155.34B | 35.69 | 9.79% | ― | 16.90% | 63.11% | |
61 Neutral | $155.16B | 120.29 | 8.41% | ― | 52.78% | ― | |
54 Neutral | HK$122.51B | 30.96 | 11.72% | 1.40% | 13.69% | 50.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
43 Neutral | HK$116.16B | -118.47 | -14.40% | ― | 33.46% | -7.60% | |
38 Underperform | HK$39.59B | -23.45 | -15.06% | ― | 38.56% | 48.26% |
Sino Biopharmaceutical Corporate Events
Sino Biopharmaceutical has announced completion of enrollment of the first patient in a Phase III clinical trial for TDI01, its independently developed, highly selective ROCK2 inhibitor for idiopathic pulmonary fibrosis (IPF), marking the first drug of its kind worldwide to reach Phase III for this indication. The candidate has shown encouraging Phase II data, including improved lung function and a favourable safety profile versus existing standard therapies, and is also being developed for chronic graft-versus-host disease, for which it has received Breakthrough Therapy Designation in China; the advancement underscores the company’s push into first-in-class therapies targeting a large, underserved global IPF population and could strengthen its position in innovative respiratory and immunology treatments if late-stage trials are successful.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical has reported positive Phase II clinical trial results for TQH3906, a Category 1 innovative oral TYK2/JAK1 JH2 allosteric inhibitor developed in-house for the treatment of moderate-to-severe plaque psoriasis. The randomized, double-blind, placebo-controlled multicenter study in 209 patients showed that at the recommended Phase II dose, TQH3906 delivered PASI 75 response rates above 90% and PASI 90 rates above 70% at 12 weeks, far exceeding placebo and demonstrating efficacy comparable to IL-17/IL-23 biologics and superior to currently marketed oral psoriasis drugs in China. Safety outcomes were favorable, with adverse events largely mild and comparable to placebo, and no new safety signals identified, underscoring the potential of TQH3906 to address a clear unmet need for highly effective, convenient oral therapies that can narrow the efficacy gap between small molecules and biologics. By targeting the pseudo-kinase domain to enhance selectivity versus traditional JAK inhibitors, the candidate could strengthen Sino Biopharmaceutical’s competitive position in immunology and dermatology, with the company planning to expand development into additional autoimmune and skin-related indications such as inflammatory bowel disease and psoriatic arthritis.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its self-developed drug, culmerciclib capsule, has been approved by the China National Medical Products Administration for marketing. This innovative drug, used in combination with fulvestrant, targets HR-positive, HER2-negative advanced breast cancer, showing significant efficacy in clinical trials by prolonging progression-free survival and improving response rates with a tolerable safety profile. The approval marks a significant milestone in addressing the unmet clinical needs in breast cancer treatment and strengthens the company’s position in the oncology market. The company is also pursuing further approvals for culmerciclib in first-line treatment and adjuvant use, highlighting its commitment to expanding treatment options for breast cancer patients.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has received approval from both the China National Medical Products Administration and the United States Food and Drug Administration for the clinical trial of its innovative drug, TQF3250, an orally administered GLP-1 receptor agonist intended for weight loss. This development is significant as it offers a more convenient oral alternative to injectable GLP-1 drugs, potentially improving patient adherence and reducing side effects. The approval also extends to the treatment of Type 2 diabetes, aligning with the company’s focus on addressing metabolic diseases and expanding its treatment offerings.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced the approval of its Rotigotine Patch by the National Medical Products Administration of China for the treatment of early idiopathic Parkinson’s disease. This approval signifies a major advancement in their transdermal patch offerings, expected to enhance patient compliance and symptom control, while solidifying the company’s position as a leader in neurological disorder treatments.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced the successful enrollment of the first patient in the Phase I clinical trial for TRD208, a first-in-class, non-opioid, multi-target, multi-modal analgesic developed by the company. TRD208 is expected to revolutionize acute pain management by blocking multiple pain-related pathways and offering peripheral anti-inflammatory effects, potentially replacing current combination therapies. This development underscores the company’s commitment to addressing unmet clinical needs and improving patient compliance while avoiding opioid-related risks.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its innovative drug, LM-350 ‘CDH17 ADC’, has received clinical trial approval from China’s National Medical Products Administration. This approval marks a significant step in addressing unmet clinical needs in treating gastrointestinal tumors, as LM-350 has shown strong anti-tumor activity, particularly in colorectal cancer models. The company aims to accelerate clinical research in China, following previous approvals from the FDA and patient enrollment in Australia.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical has announced positive interim results from its Phase III clinical study of culmerciclib, a CDK2/4/6 inhibitor, in combination with fulvestrant for the first-line treatment of HR+/HER2-advanced breast cancer. The study, presented at the ESMO Congress 2025, demonstrated significant efficacy in delaying disease progression and improving response rates compared to the control group, with manageable safety profiles. These results position culmerciclib as a potential best-in-class therapy, enhancing the company’s standing in the oncology sector and offering promising implications for stakeholders.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its new drug, TQ-B3234, a selective MEK1/2 inhibitor, has been included in the Breakthrough Therapy Designation process by the Center for Drug Evaluation of China’s National Medical Products Administration. This inclusion is for the treatment of adult plexiform neurofibromas associated with neurofibromatosis type I, a condition with significant unmet medical needs in China. The drug has shown promising results in clinical trials, with high rates of tumor shrinkage and good tolerability, and its inclusion in the Breakthrough Therapy Designation process is expected to accelerate its launch, potentially benefiting more patients sooner.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its drug TQB2102, a HER2 bispecific antibody-drug conjugate, has been included in China’s Breakthrough Therapeutic Designation process. This inclusion is expected to expedite the drug’s approval, offering a promising treatment for HER2 IHC 3+ advanced colorectal cancer, a condition with limited effective treatment options. The drug has shown a 34.8% objective response rate in clinical trials, indicating significant potential to improve patient outcomes in a field where current therapies have limited efficacy.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.